OPTIC
AI NativeAI-powered drug discovery platform for rapid molecule screening and testing, from target identification to lab validatio
Est 2022|Raised $11M
Published Jul 14, 2026
Based on typical buyer behavior in this category:
| Starting Price | Published project-based pricing available from the vendor; multiple-iteration packaged offerings noted by the vendor | Enterprise-tier pricing; not publicly standardized | Partnership/collaboration-based pricing; details available from the vendor |
| Best suited for | Teams seeking rapid hit lists from very large vendor libraries and packaged deliverables | Organizations needing end-to-end computational chemistry, physics-based methods, and collaborative informatics | Organizations seeking structure-based hit discovery via deep learning and partnership models |
| Key Strength | Published evidence of large-scale retrieval and stated deliverables (order-ready lists) | Mature ecosystem, enterprise workflows, broad method suite | Established presence in AI SBDD with multiple partnerships |
| Key Weakness | Limited public security/compliance detail; limited third-party user reviews | Cost and complexity; learning curve | Typically collaboration-based rather than productized self-serve options |
—